Collectively, current evidence supports a model [Figure 1B] in which: (1) a large fraction of early MASH resolution in ESSENCE is likely explained by significant weight loss and associated metabolic reprogramming
There is no weight-based dosing adjustment in the current label
"This requires and one-to-one GP appointment, not just an online form." It was arguably easier to access weight loss medications than to access eating disorder treatment, Dr Raykos said
CrossRef Incidence, prevalence, and prognostic impact of sarcopenia on hepatic and cardiovascular outcomes in non-cirrhotic metabolic dysfunctionassociated steatotic liver disease Rishi Chowdhary, Manjeet Kumar Goyal, Megh Patel, Rahul Chowdhary, Kirti Arora, Varun Mehta, Akash Batta, Omesh Goyal, Ashita Rukmini Vuthaluru Frontiers in Epidemiology .2026;[Epub] CrossRef Liver steatosis and fibrosis in acromegaly patients with active and controlled disease: a scoping review Karol P